

# Eberhard Standl

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6543241/eberhard-standl-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

8,620  
citations

26  
h-index

71  
g-index

71  
ext. papers

9,993  
ext. citations

10.9  
avg, IF

5.54  
L-index

#	Paper	IF	Citations
60	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 50	8.7	1
59	Guideline Development for Medical Device Technology: Issues for Consideration.. <i>Journal of Diabetes Science and Technology</i> , <b>2022</b> , 19322968221093355	4.1	
58	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 218	8.7	7
57	Heart failure outcomes and Covid-19. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 175, 108794	7.4	4
56	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108870	7.4	1
55	Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. <i>Diabetes Care</i> , <b>2020</b> , 43, 1427-1432	14.6	47
54	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2026-2034	12.3	9
53	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 161, 108054	7.4	7
52	Hypoglycaemia and its management in primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3332	7.5	4
51	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , <b>2020</b> , 43, 643-652	14.6	19
50	GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 741-743	18.1	7
49	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> 2019;42:157-163. <i>Diabetes Care</i> , <b>2019</b> , 42, e95	14.6	
48	Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 25-32	3.9	133
47	The global epidemics of diabetes in the 21st century: Current situation and perspectives. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 7-14	3.9	68
46	Targets for blood glucose: What have the trials told us. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 64-72	3.9	6
45	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , <b>2019</b> , 40, 2907-2919	9.5	22
44	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , <b>2018</b> , 41, 596-603	14.6	44

43	On the prognostic value of post-load glucose in patients with coronary artery disease. <i>European Heart Journal</i> , <b>2018</b> , 39, 2746-2748	9.5	10
42	Heart failure in diabetes: From an increased risk to a treatment target. <i>Diabetes Mellitus</i> , <b>2018</b> , 21, 399-403		1
41	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 391-402	18.1	42
40	Corrections needed to 2016 ESC and AHA guidelines on heart failure. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 325-326	18.1	6
39	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 1763-1770	14.6	46
38	Updates on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 128	8.7	36
37	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , <b>2017</b> , 70, 907-914	8.5	10
36	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 877-886	18.1	164
35	Metformin in type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 567-569	18.1	4
34	New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?. <i>Diabetes Care</i> , <b>2016</b> , 39 Suppl 2, S172-9	14.6	19
33	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , <b>2016</b> , 118, 1830-43	15.7	46
32	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 126-35	16.2	161
31	Current perspectives on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 139	8.7	51
30	Clinical features and treatment of coronary heart disease in diabetes <b>2015</b> , 1064-1078		1
29	Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1959-81	4	142
28	DPP-4 inhibitors and risk of heart failure EXAMINED. <i>Lancet, The</i> , <b>2015</b> , 385, 2022-4	40	17
27	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 232-42	59.2	1739
26	Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2014</b> , 16, 353	2.1	34

25	On the potential of acarbose to reduce cardiovascular disease. <i>Cardiovascular Diabetology</i> , <b>2014</b> , 13, 81	8.7	34
24	Glycemic control: a combination of lifestyle management and the use of drugs. <i>Cardiology and Therapy</i> , <b>2013</b> , 2, 1-16	2.8	3
23	Defending the con side: obesity paradox does not exist. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S282-6	14.6	47
22	Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2013</b> , 10, 99-114	3.3	5
21	Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 203-10	7.6	24
20	Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>Stroke</i> , <b>2013</b> , 44, 2590-3	6.7	8
19	What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2012</b> , 28 Suppl 2, 60-6	7.5	7
18	Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. <i>Diabetes and Vascular Disease Research</i> , <b>2012</b> , 9, 163-9	3.3	94
17	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , <b>2012</b> , 2,	3	19
16	Dysglycemia and abdominal obesity. <i>Current Vascular Pharmacology</i> , <b>2012</b> , 10, 678-9	3.3	8
15	The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. <i>Journal of Diabetes and Its Complications</i> , <b>2011</b> , 25, 202-7	3.2	12
14	Postprandial hyperglycemia and glycemic variability: should we care?. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S120-7	14.6	127
13	Diabetes and cardiovascular disease. <i>Clinical Research in Cardiology Supplements</i> , <b>2010</b> , 5, 27-34	3.1	1
12	The impact of glucose-lowering therapy on cardiovascular outcomes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23, 401-11	6.5	11
11	Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?. <i>Diabetes Care</i> , <b>2008</b> , 31 Suppl 2, S136-9	14.6	6
10	Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. <i>European Heart Journal</i> , <b>2008</b> , 29, 177-84	9.5	79
9	Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). <i>Diabetes Care</i> , <b>2007</b> , 30, 2773-8	14.6	212
8	Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. <i>European Heart Journal</i> , <b>2007</b> , 28, 1402-1402	9.5	329

7	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2007</b> , 28, 88-136	9.5	889
6	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAZone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet, The</i> , <b>2005</b> , 366, 1279-89	40	3186
5	Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. <i>Diabetes Care</i> , <b>2005</b> , 28, 419-20	14.6	33
4	The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2004</b> , 6, 579-88	8.1	72
3	The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. <i>European Heart Journal</i> , <b>2004</b> , 25, 1880-90	9.5	394
2	Diabetologie in Klinik und Praxis <b>2003</b> ,		3
1	New Aspects in Diabetes <b>1992</b> ,		3